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Background: Cardiac conduction disturbances are common in spondyloarthropathies such as ankylosing
spondylitis (AS). Whether their occurrence can be linked to signs and symptoms of rheumatic disease activity is an
unsettled issue addressed in this study.
Methods: In this cross-sectional study patients with AS according to modified New York criteria but without
psoriasis, inflammatory bowel disease, dementia, pregnancy, other severe diseases such as malignancy and
difficulties in answering questionnaires were invited; and 210 participated (120 men), mean age 49 years (SD 13;
range: 16–77). Questionnaires, physical examination, ECG, and laboratory tests were performed at the same visit.
Results: Cardiac conduction disturbances were common and diagnosed in 10-33%, depending on if conservative
or less conservative predefined criteria were applied. They consisted mostly of 1st degree atrio-ventricular block and
prolonged QRS duration, but one patient had a pacemaker and 7 more had complete bundle branch blocks.
Conduction abnormalities were associated mainly with age, male gender and body weight, and not with laboratory
measures of inflammation or with Bath Ankylosing Spondylitis Disease Activity Index. Neither were they associated
with the presence of HLA B27, which was found in 87% of all patients; the subtype B270502 dominated in all
patients.
Conclusions: Cardiac conduction abnormalities are common in AS, but not associated with markers of disease
activity or specific B27 subtypes. Even relatively mild conduction system abnormalities might, however, indirectly
affect morbidity and mortality.
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Chronic inflammatory disease has recently come into
focus as a risk factor for the development of cardiovas-
cular dysfunction including coronary artery disease
(CAD) [1,2]. Increased cardiovascular morbidity and
mortality seems indisputable in rheumatoid arthritis and
systemic lupus erythematosus seems to predispose for
premature CAD, especially in younger women [2]. The
situation is less clear for ankylosing spondylitis (AS) and
the other spondylarthropathies (SpA) although cardio-
vascular diseases are the leading cause of death just as* Correspondence: helena.forsblad@vgregion.se
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distribution, and reproduction in any mediumin the general population [2-4], and there is data demon-
strating an increased risk of cardiovascular disease also
in AS patients [5-7]. However, in a Brazilian registry
study on SpA cardiac manifestations were infrequently
found [8].
There is a strong immuno-genetic link between
spondylarthropathies, especially AS, and the Human
Leukocyte Antigen (HLA) B27 and the associated in-
flammatory process might not only cause rheumatic
disease but may also target cardiac function [9]. Typic-
ally cardiac involvement consists of conduction system
abnormalities and/or aortic valve insufficiency which
might require pacemaker therapy and valve replacement,
respectively. Obliterative (occlusive) endarteritis of small
vessels supplying the aortic root and the atrio-ventricular
(AV) node is a salient histological feature just as was de-
scribed in the vicinity of afflicted joints more than 50 yearsCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ment of fibrosis, which according to one autopsy study
might contribute to cardiac involvement [11].
In the present study we focus on patients with AS fulfill-
ing the modified New York criteria’s for AS [12] since AS is
a more homogeneous disease contrary to SpA comprising
different phenotypes. Furthermore, and in contrast to some
previous observations from SpA patients in general [9], a
recent study focusing specifically on AS patients reported a
relation between rheumatic disease characteristics and both
AV and intra-ventricular conduction intervals [13]. Al-
though other factors such as age and gender also were as-
sociated with signs of cardiac involvement the data might
be interpreted as supportive of a progressive inflammatory
process including fibrosis. Such data – if confirmed - have
potential mechanistic and therapeutic implications. The
present study was therefore initiated to test whether the
Dutch results were reproducible in a cross-sectional study
of a Swedish cohort of AS patients. Furthermore, we
assessed HLA B27 subtypes to explore any relation be-
tween cardiac involvement and specific subtypes.
Methods
The study cohort consists of 210 patients (120 men) with
mean age (SD; range) 49 (13; 16–77) years. They were
identified through the patient records at three different
departments of Rheumatology in Sweden, in Gothenburg
(Sahlgrenska University Hospital), Borås and Alingsås. All
patients fulfilled the modified New York criteria’s for AS
[12]. Exclusion criteria were psoriasis, inflammatory bowel
disease, dementia, pregnancy, other severe diseases such
as malignancy and difficulties in answering questionnaires.
The medical records of all AS patients registered in the
hospitals’ databases were reviewed. The flow-chart for en-
rolment is shown in Figure 1. All patients meeting study
criteria were asked to participate in this cross-sectional
AS study investigating in particular some cardiac and skel-
etal consequences of the disease. For further information
about the study design see also a previous report [14].
This report focuses on results of electrocardiographic
(ECG) recordings and the association between cardiac
conduction system abnormalities and markers of disease
activity and HLA B27 subtypes. The study was performed
according to the Helsinki Declaration of 1975, revised in
1983, approved by the Regional Ethics Committee in
Gothenburg and the patients gave written informed con-
sent to participate. The 151 patients who declined to par-
ticipate or were excluded were on average slightly younger
(46 ± 13 years), but the sex distribution was the same
among included and not included patients.
Electrocardiographic recording and analysis
Standard resting 12-lead ECG were recorded at a paper
speed of 50 mm/s, on the same occasion as bloodsamples were drawn, physical examination performed
and questionnaires completed. These ECG’s were then
read first by one author (HW) and then jointly by two
authors (HW, LB), who were unaware of patient charac-
teristics. Standard criteria used in clinical routine were
used primarily: 1st degree AV-block was diagnosed in the
presence of a PQ-interval (= PR interval) ≥ 220 ms
(0.22 s) and a broad QRS complex when the duration
was ≥ 120 ms (0.12 s). In addition, and in order to allow
comparison with the Dutch study, less conservative cri-
teria used by them were applied also in this study [13],
i.e. 1st degree AV-block was tentatively diagnosed in the
presence of a PQ interval of ≥ 200 ms (0.20 s) and a
“prolonged” QRS interval ≥ 100 ms (0.10 s). Like in the
Dutch study the PR and QRS intervals were analysed as
continuous variables and dichotomized at specified
threshold values.
Rheumatologic evaluation and blood analyses
The patients underwent physical examination by the same
physician (EK), including Bath Ankylosing Spondylitis
Metrology Index (BASMI), and answered questionnaires
about medical history, medication, Bath Ankylosing Spon-
dylitis Disease Activity Index (BASDAI), and Bath Anky-
losing Spondylitis Functional Index (BASFI) [15].
The presence of the HLA-B27 antigen and its alleles
HLA-B2701 to HLA-B2738 were assessed by HLA typing
with sequence-specific oligonucleotide primers (PCR-
SSO) by LABType®, (One Lambda, Inc, CA, USA) and use
of the Luminex platform at the Department of Clinical
Immunology and Transfusion Medicine, Sahlgrenska Uni-
versity Hospital.
Erythrocyte sedimentation rate, C-reactive protein,
haemoglobin, white blood cell count, and platelet count
were analysed consecutively by standard laboratory tech-
niques at the Departments of Clinical Chemistry.
Statistical methods
Mean and standard deviation (SD) was used for descrip-
tive purposes. Univariate and forward stepwise multi-
variate linear and logistic regression analysis was used to
assess associations between the occurrence of conduc-
tion abnormalities and ECG measures with clinical, an-
thropometric and laboratory data. Chi-square test or
Fisher’s exact two-tailed test were used for comparison
of proportions. A p-value < 0.05 was considered signifi-
cant. SAS (version 9.1, SAS Institute Inc., Cary, NC,
USA) and STATISTICA (version 10, StatSoft, Inc, Tulsa,
OK, USA) were used in the analyses.
Results
Demographic data and clinical characteristic of the 210
AS patients included in the study is presented in Table 1.
A majority (77%) of the patients were treated with non-
538 AS patients in Department Records
361 patients invited to participate
177 patients did not meet with study criteria
Other concomitant rheumatic disease, 15
Sacroileitis were not found on radiographs, 40
Radiographs of sacroiliac joints were not found, 20
Unilateral, not graded sacroileitis, 15
Inflammatory bowel disease, 21
Psoriasis, 19
Inflammatory bowel disease and psoriasis, 4
Wrong diagnosis, 4
Other severe disease such as malignancy, 9
Diseased or moved away, 9
Unable to answer questionnaires, 16
Medical records were missing, 5
210 patients included
Physical examination, questionnaires, blood 
tests, ECG
72 patients declined participation
19 patients showed exclusion criteria
Psoriasis, 7
Inflammatory bowel disease, 6
Pregnancy, 3
Unable to answer questionnaires, 3 
60 patients did not respond to invitation
Enrolment procedures & exclusions
Figure 1 Flow-chart describing the enrollment of the study cohort.
Forsblad-d’Elia et al. BMC Musculoskeletal Disorders 2013, 14:237 Page 3 of 9
http://www.biomedcentral.com/1471-2474/14/237steroidal anti-inflammatory drugs, while specific anti-
rheumatic agents and analgesics were less common and
received by 37 and 26%, respectively. Beta-blockers were
the most common cardiovascular drug; see Table 1 for
details.
Heart rhythm
The mean (SD) resting heart rate was 66 (12) beats/min;
205 had sinus rhythm, two had atrial fibrillation, one pa-
tient’s rhythm alternated between sinus and junctional
(AV nodal) rhythm, one had ectopic atrial activity, and
one pacemaker rhythm. There were 10 patients with
bradycardia (< 50 beats/min) and 4 with tachycardia
(> 100 beats/min); the minimum heart rate was 44 and
the maximum 112 beats/min.
Blood pressure
The systolic blood pressure was on average 135 mm Hg
(SD 20; range 95–190) and the diastolic pressure 77 mm
Hg (SD 10; range 50–110); 69 had a systolic pressure >
140 mm Hg, which in 17 of them was combined with a
diastolic pressure ≥ 90 mm Hg (8 of them > 90), while
two had a diastolic pressure of 90 mm Hg and normal
systolic pressures.
Atrio-ventricular and intra-ventricular conduction
The PQ interval was on average 164 (27) ms. First de-
gree AV-block defined as a PQ interval ≥220 ms waspresent in 7 patients (3.3%); and in 19 (9%) when de-
fined as a PQ interval ≥200 ms (as in ref. [13]). One pa-
tient (0.5%) had a pacemaker, but otherwise no high (2nd
or 3rd) degree AV-blocks were observed. A broad QRS
complex (≥120 ms) was observed on ECG’s from 7 pa-
tients, two had typical right bundle branch block (RBBB;
one in combination with a left anterior fascicular block,
LAFB), one had typical and another atypical left bundle
branch block (LBBB), one had a pacemaker and two had
severe intra-ventricular conduction abnormalities with-
out typical bundle branch block pattern. When using a
QRS duration ≥100 ms as a criterion of “prolonged”
QRS (as in ref. [13]), 57 patients (27%) fell into this cat-
egory, Table 2. Nine patients had isolated block in the
left anterior fascicle (LAFB; apart from the one above
with RBBB). Altogether 21 patients had atrio-ventricular
and/or intra-ventricular conduction abnormalities accord-
ing to conservative criteria (10%; 95% CI: 5.9-14.1); see
Table 3 for details. When adding first those 10 with a PQ
interval of 200–219 ms the number increased to 31
(14.7%; 95% CI: 11.0-18.4) and then those with a QRS
interval of 100–119 ms there were 39 more patients,
altogether 70 patients (33.3%; 95% CI: 26.9-39.7). While
some ECG specialists apply age differentiated PR intervals
for a diagnosis of 1st degree AV-block even in an adult
cohort, there is consensus about the criterion for broad
QRS, which is ≥120 ms (0.12 s). This is the reason why
we dichotomized the PQ interval at two threshold
Table 1 Clinical characteristics for patients with
ankylosing spondylitis participating in the study (n = 210)
Age (years) 49 (13)
Men/Women 120/90
BMI 26.0 (4.5)
Smoker≥ 6 months 105 (50%)
Rheumatologic characteristics
Age at symptom onset (years) 26 (10)
Symptom duration (years) 24 (13)
Diagnostic age (years) 36 (11)
Diagnostic duration (years) 14 (11)
BASDAI (score) 3.6 (2.1)
BASFI (score) 2.7 (2.1)
BASMI (score) 3.1 (1.6)
Blood tests
HLA B27 n (%) 183* (87)
Hemoglobin (g/L) 139 (13)
White blood cell count (×109/L) 7.0 (2.2)
Platelet count (×109/L) 298 (75)
Erythrocyte sedimentation rate (mm/h) 15 (14)
C-reactive protein (mg/L) 8.4 (10.2)
Concomitant diseases
Diabetes mellitus 6 (2.9)
Hyperlipidemia 17 (8.1)
Hypertension 56 (27)
Other cardiovascular diseases¶ 26 (12)
Coronary artery disease 6 (2.9)
Heart failure 4 (1.9)
Valvular disease 6 (2.9)
Arrhythmia 4 (1.9)





Antiarrhythmic agents 3 (1.4)
Antidiabetic agents 3 (1.4)
Antihypertensive agents 15 (7.1)
ASA 22 (11)
Betablockers 28 (13)




Lipid modulators 15 (7.1)
Table 1 Clinical characteristics for patients with
ankylosing spondylitis participating in the study (n = 210)
(Continued)
NSAID 161 (77)
TNF inhibitor 45 (21)
Warfarin 2 (1.0)
*11 were homozygous.
¶more than one is possible.
Data regarding demographic, clinical and laboratory analyses are presented as
mean (SD), while concomitant diseases and medication are presented in
numbers (%).
Abbreviations: ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II
receptor blocker, ASA acetylsalicylic acid, BMI body mass index, weight/height2,
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing
Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology
Index, DMARD disease modifying antirheumatic drug, NSAID non-steroidal
anti-inflammatory drugs, TNF tumour necrosis factor.
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below.
Comparison between clinical and ECG data
We first compared the group of 21 patients with con-
duction abnormalities according to conservative criteria
(A) with the remaining 189, and then the group of 31
patients including also the 10 with 1st degree AV-block
diagnosed based on a PQ interval of 200–219 ms (B)
with the remaining 179 patients. Multivariate analysis
showed that age (p < 0.001) and male sex (p < 0.01) were
independent determinants for group A, while symptom
duration (p < 0.001) and body weight (p < 0.0001) were
determinants for group B.
Furthermore, multivariate linear regression analysis
showed a relation between the duration of the PQ inter-
val and age (p < 0.001, male sex (p < 0.01), and body
weight (p = 0.02), and an inverse relation to leukocyte
count (p < 0.01). The QRS duration was similarly related
to male sex (p = 0.001) and body weight (p < 0.01).
The numerical data of these analyses appear in Tables 4
and 5.
HLA B27 was present in 183 patients (87%); 176 of
them had the subtype B270502 (8 were homozygous for
this subtype and 2 had other B27 subtypes as well).
B2702 was the only B27 subtype in 6 patients and
B270401 in the remaining patient. At least one B27 allele
was found in 20 of 21 (95%) patients with vs. 163 of 189
(86%) without cardiac conduction abnormalities (NS).
Applying the less conservative criteria the corresponding
figures were 26 out of 31 vs. 157 out of 179 (NS).
Group A patients (n = 21) received significantly more
cardiovascular pharmacotherapy than the remaining 189
patients, although there might be several indications for
a specific substance group; examples are beta-blockers
(33 vs. 11%; p = 0.01), ACE-inhibitors/angiotensin II re-
ceptor antagonists (38 vs. 8%; p < 0.001), diuretics and
lipid modulators (both 24% vs. 5%; p < 0.01) and ASA
Table 2 Results of electrocardiographic analysis in
patients with ankylosing spondylitis (n = 210)
Heart rate (beats/min) 66 (12)
RR-interval 930 (159)
P-wave duration** 97 (15)
PQ-interval* 164 (27)
QRS-interval** 88 (14)
QRS-interval <100* 153 (73%)
QRS-interval 100-119* 50 (24%)
QRS-interval ≥120* 7 (3.3%)
QTcB-interval** 406 (29)
Atrial fibrillation 2 (1.0%)
AV-block, 1st degree (≥220) 7 (3.3%)
AV-block, 1st degree (≥200) 19 (9%)
AV-block, 2nd degree 0
AV-block, 3rd degree 0
Left anterior fascicular block 12 (6%)
Pacemaker 1 (0.5%)
Any (≥1) conduction abnormality 21 (10%)
with AV-block, 1st degree (≥200) 31 (15%)
* n = 209 (pacemaker patient excluded).
** n = 207 (pacemaker and atrial fibrillation patients excluded).
Data are presented as mean (SD) or as otherwise stated. All intervals are in ms.
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ences for calcium antagonists and other agents with an-
tihypertensive action apart from those mentioned above.
Pharmacotherapy that might contribute to conduction
disturbances are specified for each patient in Table 3. In
only one case such therapy might have contributed to a
1st degree AV-block (the 61 years old man in Table 3).Discussion
In this Swedish cohort of 210 AS patients ECG abnor-
malities were common and cardiac conduction system
abnormalities were found in 10% according to conserva-
tive criteria and 33% when less conservative criteria were
applied. Their presence was, however, associated mainly
with age, male gender and body weight in multivariate
analyses, and not with the measures of disease activity
and functional limitations, in contrast to a recent study
discussed below [13]. The overall results of this study
therefore corroborate the view that there is not a strict
relation between the measures of disease activity and
functional limitations related to AS on one hand and
cardiac manifestations on the other [9]. Whether cardiac
conduction system abnormalities specifically or cardiac
involvement in general is a spurious event in AS patients
or determined by specific disease related or individual
factors not included in this study remain to be eluci-
dated. HLAB27 (mainly the subtype B270502) waspresent in a high proportion as expected, but the pres-
ence of one or two such alleles had no relation to the
presence of cardiac conduction abnormalities.
The recent Dutch study reported associations between
the PQ interval and age, disease duration, and BMI as
well as between the QRS duration and male gender, dis-
ease duration and BASMI [13]. There were thus both
similarities (e.g. similar proportion of patients with con-
duction abnormalities) and differences compared to the
results of our study. Some differences might at least
partly be due to selection. The Dutch study group
consisted of two differently selected subgroups; one
comprised AS patients with a diagnose duration of <
2 years and the other of AS patients with active disease
starting up with tumour necrosis factor-α inhibitors. In
contrast, our study group represents a larger and rela-
tively unselected cohort of AS patients attending hos-
pital based rheumatology clinics with a wider spectrum
of disease duration. Our patients were also on average
10 years older and had a slightly higher proportion of
women. The correlation between signs of disease activity
and cardiac involvement in the Dutch study is therefore
likely an effect of a highly selected and less representa-
tive cohort of AS patients than in the present study.
Is there a difference between AS and the other
spondylarthropathies with regard to cardiac involvement,
which can precede joint involvement in the setting of
spondylarthropathies and even occurred without such in-
volvement in the presence of HLA B27 in a man with two
brothers who had typical AS [9,16]? From the wider per-
spective of all spondylarthropathies the occurrence of typ-
ical cardiac manifestations seems to be both intermittent
(and transient) and often without relation to joint mani-
festations [9]. Even though our results do not exclude such
a relation in AS patients, if it exists it is presumably weak.
Whether analysis of modern inflammatory markers or
components can distinguish between AS patients or HLA
B27 positive individuals with/without a propensity for car-
diac involvement remains to be elucidated. One methodo-
logical issue of concern is how to assess in quantitative
terms the degree of inflammatory activity over time and
put in relation to clinical phenomena that also might vary.
This problem is obviously common to all rheumatic dis-
eases and also e.g. to stress and its relation to cardiovascu-
lar risk.
HLA B27 subtypes have been studied in relation
to other disease manifestations, but not previously
reported for cardiac involvement [17]. HLA B2705 was
the overwhelmingly dominant subtype in this cohort,
and regarded as the genetic ancestor from which the
other B27 alleles have evolved [17]. There was no sta-
tistically significant difference regarding B27 in patients
with (20 of 21) vs. without (163 of 189) cardiac conduc-
tion abnormalities.
Table 3 Characteristics of ankylosing spondylitis patients with cardiac conduction abnormalities according to
conservative criteria; PQ-interval ≥ 220 ms and/or QRS complex ≥ 120 ms (n = 21)
Age Sex Symptom
duration






30 m 8 LAFB 5.76 3.2 3 1 0
38 m 18 AV I 2.99 1.34 1.6 1 0
43 m 14 LBBB 1.95 1.07 1.4 1 0
50 m 27 AV I 5.03 3.45 2.8 1 0
52 m 13 AV I 3.9 2.43 2 1 0 HT
57 m 33 RBBB AV I 3.4 2.3 3.4 1 0 Valve disease
LAFB
59 m 36 LAFB 1 0.9 5.6 1 0
61 m 34 AV I 1 1 1.8 1 BB* HT
62 m 38 LAFB 4.65 3.88 3.6 1 (BB) Valve disease,
CAD
63 m 36 LAFB 1.38 3.69 7.2 1 0 HT
63 m 49 AV I 4.11 4.26 6 1 0
64 m 45 LAFB 0.89 2.36 6.8 1 0 Valve disease
64 m 44 LAFB 2.34 2.53 7 1 (BB) AF; HT
68 m 39 LAFB 3.44 4.99 4.2 0 0 Valve disease
68 m 42 RBBB 5 4.56 5.6 1 0 Valve disease
HT
71 m 55 LAFB 7.1 8.7 3.4 1 (BB) HT
74 m 25 LBBB NA NA 6 1 (BB) Valve disease,
heart failure
75 m 52 PM 3.84 6.65 7.2 1 (BB) Valve disease
HT
77 m 23 LAFB 6.78 7.9 6.8 1 (BB) Valve disease
HT
46 f 39 AV I 2.73 1.62 2.8 1 0
62 f 46 LAFB 3.57 3.09 3.2 2 0
Noted in the right hand column are substances that might affect atrio- and/or intra-ventricular conduction; when within brackets no clinical effect is assumed in
the patient.
Abbreviations: AI aortic valve insufficiency, AV atrio-ventricular, AV I 1st degree AV block, BASDAI, BASFI, and BASMI1, see Table 2, BB beta-blocker, CAD coronary
artery disease, CVD cardio-vascular disease, HT hypertension, IVCD intra-ventricular conduction disturbances, LAFB left anterior fascicular block, LBBB left bundle
branch block, NA not available//missing data, PM pacemaker, RBBB right bundle branch block.
* beta-blocker therapy might impair atrio-ventricular but not intra-ventricular conduction.
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This is a cross-sectional study focusing on ECG findings
and any relation to disease markers and not a prevalence
study, which would have required both a longitudinal
design and a control group. We learnt two things >
30 years ago, when an AS cohort of 68 patients were
studied by collection of all available ECG’s during
25 years: a high proportion (33%; 95% CI: 22–44) of pa-
tients had cardiac conduction abnormalities at any time
applying conservative criteria, and even the most severe
conduction abnormality 3rd degree AV-block could be
intermittent [18]. The present study has no age and sex
matched population based control group. However, as“second best” alternative we compared with a recently
acquired population sample of 547 subjects, men (n =
262) and women (n = 285) between 50 and 65 years
(mean 58; SD 4 years), and found that 1st degree AV
block was > 4 times more common among our AS pa-
tients independent of which criteria were applied (p <
0.05, chi-square test).
One-hundred and fifty-one out of 361 AS patients de-
clined to participate in the study. The most common
reasons were declining participation or not responding
to the invitation. These 151 patients were on average
slightly younger, but the sex distribution was the same
among included and not included patients. Since about
Table 4 Univariate associations between cardiac involvement and clinical data in 210 patients with ankylosing spondylitis
PQ interval QRS interval AVB IVCD AVB IVCDx
Beta (95% CI) p Beta (95% CI) p OR (95% CI) p OR (95% CI) p
Age 0.47 ( 0.19,0.74) .001 0.10 (−0.04,0.25) .17 1.088 (1.040,1.138) .0003 1.070 (1.033,1.109) .0002
Male gender 15.3 (8.2,22.4) <.0001 10.8 (7.3,14.3) <.0001 8.28 (1.88,36.53) .005 4.70 (1.73,12.80) .002
Age spt onset 0.27 (−0.12,0.66) .17 0.12 (−0.08,0.32) .24 1.002 (0.956,1.051) .92 1.015 (0.976,1.055) .46
Symptom dur. 0.38 ( 0.09,0.67) .01 0.02 (−0.13,0.17) .79 1.069 (1.030,1.111) .0005 1.055 (1.023,1.088) .0007
BASDAI −0.16 (−0.88,1.56) .86 −0.93 (−1.78,-0.09) .03 0.993 (0.801,1.232) .95 0.997 (0.832,1.194) .97
BASFI 1.68 (−0.09,3.46) .06 −0.44 (−1.33,0.45) .33 1.207 (0.984,1.479) .07 1.239 (1.041,1.474) .02
BASMI 3.42 ( 1.12,5.72) .004 0.24 (−0.95,1.44) .69 1.593 (1.224,2.074) .0005 1.566 (1.241,1.975) .0002
Length −0.61 ( 0.24,0.97) .001 0.52 ( 0.35,0.70) <.0001 1.060 (1.009,1.114) .02 1.048 (1.006,1.092) .02
Weight 0.52 ( 0.31,0.74) <.0001 0.29 ( 0.18,0.40) <.0001 1.039 (1.012,1.067) .005 1.051 (1.025,1.077) <.0001
BMI 0.66 (−0.14,1.46) .11 0.40 (−0.01,0.81) .05 0.956 (0.857,1.068) .43 1.011 (0.931,1.097) .80
Hb 0.57 ( 0.29,0.85) <.0001 0.27 ( 0.13,0.42) .0002 1.027 (0.989,1.066) .17 1.038 (1.005,1.073) .02
ESR −0.09 (−0.36,0.18) .49 −0.10 (−0.24,0.03) .14 1.007 (0.977,1.038) .65 0.991 (0.959,1.023) .56
CRP −0.04 (−0.41,0.33) .82 −0.04 (−0.22,0.15) .69 1.025 (0.994,1.058) .12 1.021 (0.992,1.052) .16
WBC −1.79 (−3.51,-0.07) .04 −0.56 (−1.43,0.32) .21 0.977 (0.787,1.213) .83 0.863 (0.700,1.063) .17
PLT −0.05 (−0.10,-0.00) .05 −0.01 (−0.04,0.01) .37 0.998 (0.992,1.004) .58 0.995 (0.990,1.001) .10
B27 alleles 6.2 (−4.8,17.2) .27 −0.2 (−5.9,5.4) .93 3.21 (0.41,24.95) .26 2.37 (0.53,10.55) .26
AVB IVCD denotes atrio-ventricular and intra-ventricular conduction disturbances according to standard (conservative) criteria (n = 21).
AVB IVCDx denotes such disturbances according to less conservative criteria (n==31) for comparison with ref. [13].
Abbreviations: PQ interval = duration from P-wave to QRS complex; QRS interval = duration of QRS complex; AVB atrio-ventricular Block; IVCD intra-ventricular
conduction disturbances: BASDAI Bath Ankylosing Spondylitis Disease Activity Index; BASFI Bath Ankylosing Spondylitis Functional Index; BASMI Bath Ankylosing
Spondylitis Metrology Index; BMI Body Mass Index; Hb Hemoglobin (g/L); ESR Erythrocyte Sedimentation Rate (mm/h); CRP C-reactive protein (mg/L); WBC White
Blood Cells (×109/L); PLT Platelet Count (×109/L).
Beta regression coefficient; CI confidence interval; OR = odds ratio.
Univariate associations (univariate linear regression and logistic regression).
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distribution did not differ we do not believe that this
limitation should substantially influence our findings.
Hypertension and coronary disease were found in
similar proportions of AS patients with and without con-
duction abnormalities and none of our AS patients with
conduction abnormalities had diabetes or hyperlipid-
emia. Therefore no adjustments for these variables have
been applied in the statistical analyses. Because there is aTable 5 Multivariate analyses between cardiac involvement and
PQ interval QRS interval
Beta (95% CI) p Beta (95% CI) p
Age 0.48 (0.21,0.74) .0005
Symptom dur.
Weight 0.32 (0.06,0.57) .02 0.18 (0.05,0.31) .0
WBC −2.12 (−3.70,-0.53) .009
Male gender 10.2 (2.1,18.3) .01 7.0 (2.8,11.2) .0
AVB IVCD denotes atrio-ventricular and intra-ventricular conduction disturbances ac
AVB IVCDx denotes such disturbances according to less conservative criteria (n = 31
PQ interval = duration from P-wave to QRS complex; QRS interval = duration of QRS
disturbances; WBC White Blood Cells (×109/L).
Beta regression coefficient; CI confidence interval; OR = odds ratio.
Multivariate analyses (forward stepwise multivariate linear regression and logistic reknown relation between aortic and mitral valvular dis-
ease and AS it was no surprise that this finding was
over-represented among those with cardiac conduction
abnormalities.
BASMI measures most of all spinal mobility and both
disease and aging related factors might contribute to a
higher score. BASFI and BASDAI on the other hand
are based on the patients’ report on the ability to per-
form daily physical activities and their perception ofclinical data in 210 patients with ankylosing spondylitis
AVB IVCD AVB IVCDx
OR (95% CI) p OR (95% CI) p
1.091 (1.042,1.143) .0002
1.062 (1.026,1.098) .0003
07 1.055 (1.027,1.083) <.0001
01 9.64 (2.12,43.87) .003
cording to standard (conservative) criteria (n = 21).
) for comparison with ref. [13].
complex; AVB = atrio-ventricular Block; IVCD intra-ventricular conduction
gression).
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when patients are not seen because they seek medical
care due to worsening of the disease, these two latter
scores naturally vary.
In this study we focused on patients fulfilling the
modified New York criteria’s for AS but in the future it
would also be of interest to assess whether or not car-
diac conduction disturbances are evenly distributed
across different phenotypes of spondylarthropathies.
Implications
Does a prolonged PQ-interval matter? It is certainly not an
indication for permanent pacemaker therapy. Recent stud-
ies have, however, pointed to an increased risk for atrial fib-
rillation (which might be intermittent or “paroxysmal” and
easily overlooked) in patients with a prolonged PQ-interval
or 1st degree AV-block [19,20]. Mechanistically there seems
to be a relation not only to impaired ventricular filling
(preload) but also to the occurrence of mitral valve insuffi-
ciency with possible secondary effects on both atrial and
ventricular structure and function [21]. Atrial fibrillation in
turn is associated with a 5-fold increased risk for stroke, a
doubled mortality risk and an increased risk for heart fail-
ure apart from reduced quality of life [22].
A complete LBBB (and other intraventricular conduc-
tion disturbances) may cause ventricular dyssynchrony
with delayed left ventricular activation especially of the
lateral basal parts and contribute to the development of
heart failure, sometimes amenable to pharmacologic
therapy and if needed cardiac resynchronisation therapy
with right and left ventricular pacing [23]. Typical AS
(or HLA B27) associated cardiac conduction system ab-
normalities are not only common but might thus even
in seemingly less severe forms lead to clinically signifi-
cant cardio-vascular morbidity, an issue which seems to
have been forgotten in the new-born wake of interest for
inflammation and cardiovascular risk [1-3].
Cardiac involvement is common in AS and other
spondyloarthropathies and ECG is therefore suggested
to be part of the routine evaluation of such patients, in
particular when the patient presents with unspecific
symptoms such as tiredness/fatigue, dyspnoea, and de-
creased physical capacity which might be related to car-
diac conduction abnormalities and arrhythmias.
Conclusions
Cardiac conduction abnormalities were common in this
cross-sectional study but mainly associated with factors
unrelated to rheumatic disease activity. Even relatively
mild conduction system abnormalities might, however,
have hemodynamic consequences of clinical importance.
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